Results 121 to 130 of about 2,479 (207)

Prescriber adherence to treatment guidelines for monoclonal antibodies against Calcitonin Gene-Related Peptide in migraine prophylaxis - a register-based cohort study. [PDF]

J Headache Pain
Nordenmalm S, Malmström RE, Freyland S, Nilsson Remahl AIM, Wirdefeldt K, Ekheden I.   +5 more
europepmc   +1 more source

The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectiveness. [PDF]

Neurol Sci
Vernieri F, Ambrosini A, Bartolini M, Cevoli S, Coppola G, D'Onofrio F, De Simone R, Granato A, Guerzoni S, Prudenzano MP, Rainero I, Rao R, Tassorelli C, Kokturk P, Cepparulo M.   +14 more
europepmc   +1 more source

Long-term real-world effectiveness and safety of fremanezumab in 1140 patients with migraine and at least 6 months of treatment: third interim analysis of the pan-European PEARL study. [PDF]

Neurol Sci
Ashina M, Mitsikostas DD, Amin FM, Kokturk P, Schankin CJ, Sahin G, Pozo-Rosich P, Dorman PJ, Nežádal T, Poole AC, Martins IP, Sumelahti ML, Ramirez Campos V, Ahn AH, Akcicek H, Tassorelli C.   +15 more
europepmc   +1 more source

Botulinum Toxin Type A for the Prevention of Migraines: An Umbrella Review of Systematic Reviews. [PDF]

Toxins (Basel)
Chamani G, Jasim H, Minston A, Dias MF, Poluha RL, Gonçalves DAG, Christidis M, Al-Moraissi EA, Christidis N, De la Torre Canales G, Ernberg M.   +10 more
europepmc   +1 more source

Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study Group. [PDF]

Eur J Neurol
Argyriou AA, Dermitzakis EV, Xiromerisiou G, Chondrogianni M, Foska A, Soldatos P, Mavraki E, Rikos D, Litsardopoulos P, Tsivgoulis G, Vikelis M.   +10 more
europepmc   +1 more source

Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed. [PDF]

Adv Ther
Mitsikostas DD, Awad SF, Kongerslev R, Boserup LP, Lee XY, Phul R, Sacco S.   +6 more
europepmc   +1 more source

Prescription of Monoclonal Antibodies Against Calcitonin Gene-Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data. [PDF]

Eur J Neurol
Zebenholzer K, Gleiss A, Reichardt B, Gall W, Wöber C.   +4 more
europepmc   +1 more source

Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review. [PDF]

J Headache Pain
Hoehne CL, Overeem LH, Sanchez-Del-Rio M, Deligianni C, Gil-Gouveia R, Versijpt J, Amin FM, Lampl C, Ryliskiene K, Tronvik E, Coppola G, Holland PR, MaassenVanDenBrink A, Martelletti P, Reuter U, European Headache Federation, EHF.   +16 more
europepmc   +1 more source

Fremanezumab for the Preventive Treatment of Migraine

To evaluate the efficacy of monthly or quarterly fremanezumab in patients with chronic migraine or episodic migraine and documented inadequate response to 2, 3, or 4 classes of prior migraine preventive medications. This is an exploratory analysis of a randomized, double-blind, placebo-controlled, phase 3b trial for patients with chronic migraine or ...
Pazdera, Ladislav||, Cohen, Joshua M., Ning, Xiaoping, Campos, Verena Ramirez, Yang, Ronghua, Pozo-Rosich, Patricia||   +5 more
openaire   +1 more source

Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder: The UNITE Randomized Clinical Trial. [PDF]

JAMA Neurol
Lipton RB, Ramirez Campos V, Roth-Ben Arie Z, Galic M, Mitsikostas D, Tassorelli C, Denysenko L, Cohen JM.   +7 more
europepmc   +1 more source